Bioxyne Limited · ASX:BXN
Bioxyne — Investor Presentation (November 2024)
22 slides from Bioxyne's investor presentation, Nov 18, 2024
Slide 1: Becoming Australia’s leading manufacturer & wholesaler of novel medicines
Becoming Australia’s leading manufacturer & wholesaler of novel medicines ASX:BXN Investor Presentation | November 2024 Bioxyne | ASX:BXN | Investor Presentation | November 2024 | 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this p
Slide 3: Investment Highlights
Investment Highlights Strong revenue growth, Extensive Good First company licensed Diversified core of recording a 119% lift to Manufacturing Practice by TGA in Australia to healthcare & wellness $4.6m for Q1 FY25 on pcp, (GMP) licence issued by manufacture Psilocybin & revenue streams, from achievi
Slide 4: Executive Summary
Executive Summary Positioned to become Australia’s leading manufacturer of novel medicines & health products, with a core focus on cannabis products through its Breath Life Sciences (BLS) brand Bioxyne’s Core Brands $4.6m ~36% Total Revenue for FY24 Gross Profit Margin Q1 FY25, a 119% increase after
Slide 5: Company Overview
Company Overview Bioxyne | ASX:BXN | Investor Presentation | November 2024 | 5
Slide 6: Commercial Milestones to Date
Commercial Milestones to Date Acquisition of Launch CanXChange, Completed PICs GMP Strategic alliance with CY BLS manufactures BXN announces cash Production & supply of BXN Breathe Life providing accredited facility in QLD, with Biopharma AG to develop Australia’s first GMP flow positive quarter psi
Slide 7: Breathe Life Sciences’ Supply Chain Model
Breathe Life Sciences’ Supply Chain Model Product List1,2 Wholesalers Herb, Dried (Flower) Prescriptions - 3,347,909 Oral Liquid Prescriptions - 3,025,118 Clinics Capsules Prescriptions – 339,791 Inhalation (Vapes) Prescriptions – 133,116 Raw Materials Manufacture Pharmacy Patient1 Purchase raw Prod
Slide 8: Significant Market Opportunity
Significant Market Opportunity Bioxyne has established a global supply, manufacture and distribution network, now rapidly scaling revenues to service both the B2B & B2C market across all products. $39.1B Europe $12.5B Asia $37.9B North America Estimated Market Size Suppliers $9.1B Latin America & Ex
Slide 9: Growth Strategy
Growth Strategy Bioxyne | ASX:BXN | Investor Presentation | November 2024 | 9
Slide 10: Near-Term Growth Strategy
Near-Term Growth Strategy Exceed revenue Secure new contracts to Continue to generate Quickly scale and guidance of $20.0m build on growing topline positive cashflow & improve efficiencies to revenue growth EBITDA generation enhance margins Materially increase Expand manufacturing Complete regulator
Slide 11: Multiple High-Value Manufacture & Supply Agreements
Multiple High-Value Manufacture & Supply Agreements Contracts for manufacture of key products continue to grow, with a total of $47.5m in contracted pipeline of purchase orders Contract 1 Contract 2 Additional Contracts Total Contracts THC & CBD Pastilles THC & CBD Pastilles THC & CBD Pastilles THC
Slide 12: Expanding Production Capability
Expanding Production Capability Recent investment into additional equipment & facilities will provide substantial increased production capability at Australia sites SKU THC Flower THC & CBD Pastilles Vapes Oral Liquids / Oils Current Output $34,000 – $40,000 $99,000 $27,000 $35,000 (revenue per day)
Slide 13: Key Market Opportunity
Key Market Opportunity Bioxyne | ASX:BXN | Investor Presentation | November 2024 | 13
Slide 14: Growing Domestic Demand for Medicinal Cannabis
Growing Domestic Demand for Medicinal Cannabis Australian Medicinal Cannabis Prescriptions1 Australian Cannabis Market2 $1,000m 2024 137,180 2023 127,790 $800m 2022 114,930 $600m 2021 121,940 2020 57,710 $400m 2019 25,160 $200m 2018 2,560 2017 231 - 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Slide 15: Cannabis & CBD Market in Europe
Cannabis & CBD Market in Europe Europe’s medical cannabis market continues to see strong growth, presenting BXN with a significant opportunity to expand manufacturing, supply and distribution capabilities Legislation & Regulation of Cannabis in Europe1 BLS Europe Growth Opportunity3,4 Germany UK Cze
Slide 16: Financial Overview
Financial Overview Bioxyne | ASX:BXN | Investor Presentation | November 2024 | 16
Slide 17: Cash Flow Positive
Cash Flow Positive Strong outlook for remainder of FY25 and beyond, following execution of significant contracts, providing revenue potential of over $20m p.a., with customer base continuing to build CASH RECEIPTS & NET CASH USED IN OPERATING ACTIVITIES ($000's) +117% $5,772 • Bioxyne has delivered
Slide 18: Financial Performance
Financial Performance Strong performance from provision of psychoactive medicines, supplements and foods made from cannabis, psilocybin & MDMA BXN REVENUS FROM OPERATIONS ($000’s) $25,000 100% ~$9.66m ~$4.6m $20,000 $20,000 80% Revenue for Q1 FY25 Total Revenue for FY24 (July-2024) $15,000 60% $10,0
Slide 19: Appendix
Appendix Bioxyne | ASX:BXN | Investor Presentation | November 2024 | 19
Slide 20: Experienced Leadership Team
Experienced Leadership Team Mr. Anthony Ho Samuel Watson Jason Hine Guy Robertson B. Com (UNSW), CA, FAICD, FCIS, FGIA BSc Finance and Economics BA Economics and Commerce B. Com (Hons.) CA Non-executive Chairman Managing Director Executive Director CFO & Company Secretary • Tony is an experienced co
Slide 21: Corporate Overview
Corporate Overview $0.021 180m $0.014 120m $0.007 60m - - Nov-23 Feb-24 May-24 Aug-24 Nov-24 Volume Share Price CORPORATE SNAPSHOT (15/11/2024) MAJOR SHAREHOLDERS Shareholder Shares (m) % Shares on Issue ~2,049m Breathe International Ltd 576,268,527 28.16 Options & Performance Rights 42.9m Kirkman T
Slide 22: Contact
Contact: Samuel Watson – Managing Director info@bioxyne.com James Emonson – Corporate Advisor, Alpine Capital jemonson@alpinecapital.au Bioxyne | ASX:BXN | Investor Presentation | November 2024 | 22